11 юли 2021

NITROSAMINE CONTENT IN ANTIHYPERTENSIVE MEDICATION, THE POSSIBLE CANCER DEVELOPMENT AND THE BIG PHARMA PROTECTION – A NEVER ENDING STORY.

Посетете: https://www.gmp-compliance.org/gmp-news/sartan-medicinal-products-emas-assesment-report-defines-nitrosamine-limits-and-reporting-deadlines